" class="no-js "lang="en-US"> Alira Health Accelerates Global Growth & Secures $58M in Funding
Monday, April 15, 2024

Alira Health Accelerates Global Growth and Secures Additional $58M in Funding

Alira Health, a global healthcare advisory, clinical research and technology company, announced it secured an additional US$58 million in capital funding, further strengthening its position as a global leader in humanizing healthcare. This investment accelerates Alira Health’s delivery of patient-centric, technology-enabled healthcare solutions.

Alira Health is focused on new opportunities brought into effect in the United States by federal rules preventing the blocking of electronic health information (EHI) under the 21st Century Cures Act. This allows patients ownership and control over their own data, and is seen as a game-changer for patients’ ability to engage in healthcare in powerful new ways. In an interview with Patient Engagement HIT, Micky Tripathi, the leader of the US Office of the National Coordinator for Health IT (ONC) noted that “patient data access under the 21st Century Cures Act is a first step in building a culture of patient empowerment.”

“With the Cures Act empowering patients to access their own data, Alira Health is well positioned with a significant tailwind in our favor, as we have been preparing for this major paradigm shift for years,” said Gabriele Brambilla, CEO and Co-Founder of Alira Health. “We are executing on our winning strategy to become a patient-centric solutions provider, enabled by innovative technologies that will collect clinical and real-world data directly from patients, powerfully informing the development of new drugs and devices. Our investors are excited to share our vision and support us in our mission to positively impact the life of every patient.”

“At Alira Health, we are ready for this revolutionary new world in which patients own their data, and are empowered not only to improve their own health, but also to help improve the health of others and solve medical problems,” said Benjamin Chambon, CCO and Co-Founder of Alira Heath. “Patient data will illuminate the patient journey for life sciences companies, guiding the direction of research and development. The result will be the democratization of life sciences research.”

Alira Health raised $35M in funding in 2021 and $40M in 2022, in two rounds led by Creadev.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more